An open-label, multicenter, phase II study of ceritinib in patients with advanced ALK+ non-lung solid tumors and hematological malignancies (ASCEND-10). A phase Ib ...
When using patient-reported outcomes in clinical practice, the measure matters: Results from an RCT.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results